[1]周云△,赵丹.胃癌内科治疗现状[J].郑州大学学报(医学版),2009,(05):938-941.
点击复制

胃癌内科治疗现状()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2009年05期
页码:
938-941
栏目:
应用研究
出版日期:
2009-09-01

文章信息/Info

作者:
周云赵丹
河南省人民医院肿瘤科郑州450003
关键词:
胃癌化疗分子靶向治疗基因治疗免疫治疗

参考文献/References:

[1]秦叔逵,龚新雷.晚期胃癌化疗现状和新进展[J].临床肿瘤学杂志,2006,11(9):641
[2]Earle CC,Maroun JA.Adjuvant chemotherapy after curative resection for gastric cancer in nonAsian patients:revisiting a metaanalysis of randomized trials[J].Eur J Cancer, 1999, 35 (7):1 059
[3]Chipponi J, Huguier M, Pezet D, et al.Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer[J]. Am J Surg,2004,187(3):440
[4]De Vita F, Giuliani F, Orditura M,et al.Adjuvant chemotherapy with epirubicin, leucovorin, 5fluorouracil and etoposide regimen in resected gastric cancer patients:a randomized phase Ⅲ trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)[J].Ann Oncol,2007,18(8):1 354
[5]Sakuramoto S,Sasako M,Yamaguchi T,et al.Adjuvant chemotherapy for gastric cancer with S1,an oral flroropyrimidine[J].N Engl J Med,2007,357(18):1 810
[6]Bajetta E, Buzzoni R, Mariani L,et al.Adjuvant chemotherapy in gastric cancer: 5year results of a randomized study by the Italian Trials in Medical Oncology(ITMO) Group[J]. Ann Oncol,2002,13(2):299
[7]Nashimoto A, Nakajima T, Furukawa H,et al.Randomized trial of adjuvant chemotherapy with mitomycin,Fluorouracil, and Cytosine arabinoside followed by oral Flurouracil in serosa negative gastric cancer. Japan Clinical Oncology Group 92061[J]. J Clin Oncol,2003,21(12):2 282
[8]Cunningham D,Allum WH,Stenning SP,et al.Perioperative chemotherapy versus alone for resectable gastroessphageal cancer[J].N Engl J Med,2006,335(1):11
[9]Wang LB,Shen JG,Xu CY,et al. Neoadjuant chemotherapy versus surgery alone for locally advanced gastric cancer:a retrospective comparative study[J]. Hepatogastroenterology,2008,55(86/87):1 895
[10]Kinoshita T,Sasako M,Sano T,et al.Phase Ⅱ trial of S1 for neoadjuvant chemotherapy against scirrhous gastric cancer(JCOG 0002)[J].Gastric Cancer,2009,12(1):37
[11]Guo MG,Zheng Q,Cheng Z,et al.The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer[J].Surg Oncol,2008:8[Epub ahead of print]
[12]Hofler H, Langer R, Ott K, et al. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract[J]. Recent Results Cancer Res,2007,176:33
[13]Ajani JA, Moisevenko VM, Tjulandin S, et al.Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase Ⅲ trial for advanced gastric or gastroesophageal adenocarcinoma :the V325 Study Group[J].J Clin Oncol,2007,25(22):3 210
[14]宋恕平,梁军,苗志敏.中国临床肿瘤学教育专辑[M](2005).青岛:中国海洋大学出版社,2005:144
[15]Dank M,Zaluski J,Barone C,et al.Randomized phase Ⅲ study comparing irinotecan combined with 5fluorouracil and folinic acid to cisplatin combined with 5fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction[J]. Ann Oncol,2008,19(8):1 450
[16]Pinta C, Di Fabio F, Siena S, et al. Phase Ⅱ tudy of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)[J].Ann Oncol,2007,18(3):510
[17]Kishida O,Miyazaki Y,Murayama Y,et al.Gefitinib(Iressa,ZD1839) inhibits SN38triggered EGF signals and IL8 productuin in gastric cancer cells[J].Cancer Chemother Pharmacol,2005,55(6):584
[18]Gravalos C,Jimeno A.HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target[J].Ann Oncol,2008,19(9):1 523
[19]Gong SJ,Jin CJ,Rha SY,et al.Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines[J].Cancer Lett,2004,214(2):215
[20]Labonte MJ,Manegold PC,Wilson PM,et al.The dual EGFR/HER2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN38[J]. Int J Cancer,2009:17[Epub ahead of print]
[21]Shah MA,Ramanathan RK,Ilson DH,et al.Multicenter phase Ⅱ study of irinotecan,cisplatin,and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma[J].J Clin Oncol,2006,24(33):5 201
[22]方凤奇,朱青山,刘基巍.注射用重组改构人肿瘤坏死因子治疗恶性腹水的价值研究[J].西部医学,2006,18(3):264
[23]刘星,张祥福,卢辉山,等. 重组改构人肿瘤坏死因子治疗晚期胃癌的随机对照临床研究[J].中国医药生物技术,2006,1(1):46
[24]Ohshita A,Yamaguchi Y,Minami K,et al.Generation of tumorreactive effector lymphocytes using tumor RNAintroduced dendritic cells in gastric cancer patients[J].Int Oncol,2006,28(5):1 163
[25]Jang YJ, Kim YS, Kim WH. Oncogenic effect of Pololike kinase 1 expression in human gastric carcinomas[J]. Int J Oncol,2006,29(3):589
[26]Jeong YW,Kin KS,Oh JY,et al.Exogenous wildtype p16INK4A gene induces delayed cell proliferation and promotes chemosensitivity through decreased pRB and increased E2F1 expression[J].Int J Mol Med,2003,12(1):61
[27]Tong QS, Zheng LD,Wang L, et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells[J]. Cancer Gene Ther,2005,12(5):509
[28]Lavarino BC,Pilotti S, Oggionni M, et al. p53 gene status and responese to platinum/paclitaxelbased chemotherapy in advanced ovarian carcinoma[J].J Clin Oncol,2000,18(23):3 936
[29]Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters[J].Int J Cancer,2002,98(3):323
[30]尹新华,凌虹,郭彩玲,等.腺病毒介导的P53基因抗人胃腺癌增殖的研究[J].中国公共卫生,2003,19(3):257

相似文献/References:

[1]孙勇),高剑波)#,周志刚),等.CT引导下125I粒子植入联合化疗治疗晚期胰腺癌25例体会*[J].郑州大学学报(医学版),2009,(06):1273.
[2]周云△.顺铂和5氟尿嘧啶联合替尼泊苷或依托泊甙治疗晚期胃癌疗效对比*[J].郑州大学学报(医学版),2009,(05):955.
 ZHOU Yun.Comparison of regimen VCF and ECF in treatment of advanced gastric cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(05):955.
[3]周云△.替尼泊苷和5氟尿嘧啶联合奥沙利铂或顺铂治疗晚期胃癌疗效对比[J].郑州大学学报(医学版),2009,(05):957.
 ZHOU Yun.Comparison of regimen VOF and VCF in treatment of advanced gastric cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(05):957.
[4]常方方,高明,周云#.奥沙利铂联合顺铂对体外培养BGC823细胞增殖及Bcl2、Bax、Caspase3蛋白表达的影响[J].郑州大学学报(医学版),2009,(02):359.
 CHANG Fangfang,GAO Ming,ZHOU Yun.Effects of OXA and DDP on cell proliferation and Bcl2,Bax,Caspase3 expression of BGC823 cells in vitro[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(05):359.
[5]林锐)△,李晓丽),褚燕君).胃癌组织中诱导型一氧化氮合酶、核转录因子κB的表达[J].郑州大学学报(医学版),2009,(02):371.
 LIN Rui),LI Xiaoli),CHU Yanjun).Expression of iNOS and NFκB in human gastric carcinoma tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(05):371.
[6]刘国红△,杨继要,呼琳,等.胃腺癌及正常胃黏膜组织蛋白质组双向电泳图谱分析[J].郑州大学学报(医学版),2009,(04):786.
 LIU Guohong,YANG Jiyao,HU Lin,et al.Analysis of the twodimensional electrophoresis maps of gastric carcinoma and paired normal mucosa[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(05):786.
[7]赵春临),乔军波),张谢夫)#,等.胃癌组织中67LR和半乳糖凝集素3基因mRNA的表达[J].郑州大学学报(医学版),2009,(04):791.
 ZHAO Chunlin),QIAO Junbo),ZHANG Xiefu),et al.Detection of 67LR and galectin3 mRNA in gastric carcinoma tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(05):791.
[8]盛光辉△.谷氨酰胺对胃癌患者术后血清白细胞介素8和热休克蛋白70水平的影响[J].郑州大学学报(医学版),2009,(04):822.
 SHENG Guanghui.Effects of glutamine on postoperative serum IL8 and HSP70 levels in patients with gastric carcinoma[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(05):822.
[9]路永平),程志).儿童白血病72例多周期化疗前后心电图分析[J].郑州大学学报(医学版),2009,(04):892.
[10]王绍霞.双孔胸腹引流导管在恶性肿瘤心包积液中的应用[J].郑州大学学报(医学版),2009,(04):927.

备注/Memo

备注/Memo:
△男,1959年生,硕士,教授,研究方向:肿瘤的基础与临床,Email:zhy1336@yahoo.com.cn
更新日期/Last Update: 2010-05-14